Full Text
Type 2 diabetes mellitus is one of the fastest-growing chronic diseases worldwide and represents a major public health challenge. The rapid increase in sedentary lifestyles, unhealthy dietary habits, urbanization, and population aging has contributed to the parallel rise in obesity and cardiovascular disease. These disorders are not isolated clinical entities but rather components of a complex metabolic syndrome characterized by insulin resistance, chronic inflammation, endothelial dysfunction, abnormal lipid metabolism, and accelerated atherosclerosis.
Obesity is considered the principal modifiable risk factor for the development of T2DM. Excess adipose tissue functions as an active endocrine organ that secretes adipokines, inflammatory cytokines, free fatty acids, and hormones influencing glucose metabolism and vascular homeostasis. Persistent adipose tissue inflammation contributes to insulin resistance by impairing insulin receptor signaling in skeletal muscle, liver, and adipose tissue. As pancreatic β-cells progressively lose their compensatory capacity, persistent hyperglycemia develops, leading to the clinical manifestation of diabetes.
Patients simultaneously affected by T2DM and obesity demonstrate a markedly increased incidence of cardiovascular disease. Coronary artery disease, ischemic stroke, peripheral arterial disease, heart failure, atrial fibrillation, and chronic kidney disease occur more frequently than in individuals without metabolic disorders. Cardiovascular complications account for the majority of deaths among patients with T2DM, emphasizing the necessity of early and aggressive risk factor management.
Hyperglycemia contributes directly to vascular injury through several pathological mechanisms. Chronic elevation of blood glucose promotes oxidative stress, formation of advanced glycation end-products, activation of inflammatory pathways, endothelial dysfunction, vascular smooth muscle proliferation, and accelerated atherosclerotic plaque formation. Simultaneously, obesity-associated dyslipidemia and hypertension further amplify cardiovascular damage.
Insulin resistance plays a central role in disease progression. Reduced insulin sensitivity results in increased hepatic glucose production, impaired peripheral glucose uptake, excessive lipolysis, elevated circulating free fatty acids, and chronic hyperinsulinemia. These metabolic abnormalities contribute not only to poor glycemic control but also to hypertension, dyslipidemia, hepatic steatosis, and chronic inflammation.
Early diagnosis and comprehensive cardiovascular risk assessment are essential components of patient management. Evaluation should include glycated hemoglobin (HbA1c), fasting plasma glucose, lipid profile, renal function, urinary albumin excretion, blood pressure, body mass index, waist circumference, smoking history, family history, and assessment of subclinical cardiovascular disease. Risk stratification allows clinicians to individualize treatment according to the patient's overall cardiovascular profile.
Lifestyle modification remains the cornerstone of therapy. Nutritional intervention emphasizing calorie restriction, increased consumption of vegetables, whole grains, lean protein, and unsaturated fats significantly improves metabolic control. Regular physical activity enhances insulin sensitivity, reduces visceral adiposity, improves endothelial function, lowers blood pressure, and decreases cardiovascular mortality. Weight reduction of even 5–10% of initial body weight produces clinically meaningful improvements in glycemic control and cardiovascular risk.
Modern pharmacological therapy has evolved beyond glucose lowering alone. Glucagon-like peptide-1 receptor agonists promote weight loss, improve glycemic control, suppress appetite, delay gastric emptying, and reduce major adverse cardiovascular events. Sodium-glucose cotransporter-2 inhibitors lower plasma glucose by increasing urinary glucose excretion while simultaneously reducing heart failure hospitalization, slowing chronic kidney disease progression, and improving cardiovascular survival.
Comprehensive cardiovascular risk management also requires optimal control of hypertension and dyslipidemia. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are recommended for patients with hypertension or diabetic kidney disease, while statins remain the first-line therapy for lipid reduction. Antiplatelet therapy may be indicated in selected patients with established atherosclerotic cardiovascular disease.
Recent advances in digital medicine have further strengthened chronic disease management. Continuous glucose monitoring systems, wearable health devices, mobile applications, telemedicine, and artificial intelligence-assisted decision support enable more precise metabolic monitoring, improve treatment adherence, and facilitate personalized therapeutic adjustments.
A multidisciplinary approach involving endocrinologists, cardiologists, nephrologists, dietitians, diabetes educators, clinical pharmacists, psychologists, and primary care physicians has demonstrated superior outcomes compared with isolated specialist care. Coordinated management improves glycemic control, reduces hospitalization, delays complications, and enhances patient quality of life.
The objective of this review is to evaluate contemporary approaches to the comprehensive management of patients with type 2 diabetes mellitus, obesity, and high cardiovascular risk, emphasizing evidence-based therapeutic strategies that improve metabolic control, reduce cardiovascular complications, and optimize long-term clinical outcomes.
2. Materials and Methods
A prospective observational study was conducted between January 2023 and May 2025 at the Departments of Endocrinology and Cardiology of three tertiary referral hospitals. The primary objective was to evaluate the effectiveness of a comprehensive multidisciplinary management strategy in patients with type 2 diabetes mellitus (T2DM), obesity, and high cardiovascular risk.
A total of 420 participants were enrolled. The study population included adults aged 35–75 years with confirmed T2DM for at least one year, body mass index (BMI) ≥30 kg/m², and high cardiovascular risk defined by established atherosclerotic cardiovascular disease or the presence of multiple cardiovascular risk factors such as hypertension, dyslipidemia, chronic kidney disease, smoking, or a family history of premature cardiovascular disease.
Patients with type 1 diabetes mellitus, pregnancy, active malignancy, severe hepatic insufficiency, end-stage renal disease requiring dialysis, or acute cardiovascular events within the previous three months were excluded.
Baseline clinical assessment included demographic data, diabetes duration, smoking history, physical activity, dietary habits, medication use, and previous cardiovascular events. Anthropometric measurements included body weight, height, BMI, waist circumference, and blood pressure.
Laboratory investigations included fasting plasma glucose, glycated hemoglobin (HbA1c), fasting insulin, lipid profile, renal function tests, liver enzymes, urinary albumin-to-creatinine ratio, high-sensitivity C-reactive protein (hs-CRP), serum uric acid, and electrolytes.
Cardiovascular evaluation consisted of electrocardiography, transthoracic echocardiography, carotid Doppler ultrasonography, ankle-brachial index measurement, and assessment of estimated 10-year cardiovascular risk using internationally accepted prediction models.
All participants received individualized treatment plans consisting of structured nutritional counseling, supervised physical activity recommendations, smoking cessation support when necessary, blood pressure management, lipid-lowering therapy, optimized glucose-lowering medications, and regular follow-up every three months.
Patients requiring pharmacological intensification received modern glucose-lowering agents according to current international recommendations, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors whenever clinically appropriate.
The primary study outcomes included improvement in glycemic control, weight reduction, blood pressure normalization, lipid profile improvement, reduction in inflammatory markers, and occurrence of cardiovascular events during follow-up.
Statistical analysis was performed using validated biomedical statistical software. Continuous variables were expressed as mean ± standard deviation, while categorical variables were reported as frequencies and percentages.
Among the 420 participants, the average duration of diabetes exceeded eight years, and the majority presented with multiple cardiovascular risk factors. Hypertension and dyslipidemia were the most common accompanying conditions, followed by diabetic kidney disease and previous coronary artery disease.
Implementation of the multidisciplinary treatment program resulted in significant improvement in metabolic control. Mean HbA1c values declined progressively during follow-up, while fasting plasma glucose levels demonstrated sustained reduction. Patients receiving GLP-1 receptor agonists experienced greater improvements in glycemic control together with clinically meaningful weight loss.
Average body weight and waist circumference decreased substantially following combined dietary intervention, regular physical activity, and optimized pharmacotherapy. Reduction of visceral adiposity was accompanied by improvement in insulin sensitivity and lower circulating inflammatory biomarkers.
Blood pressure control improved significantly after optimization of antihypertensive therapy. Most patients achieved recommended blood pressure targets by the end of the observation period. Lipid management with statin therapy resulted in lower low-density lipoprotein cholesterol concentrations and improved overall lipid profiles.
Markers of systemic inflammation, including high-sensitivity C-reactive protein, declined during treatment, indicating reduced chronic inflammatory activity associated with obesity and diabetes.
Cardiovascular assessment demonstrated stabilization of cardiac function in most patients. The incidence of hospitalization for heart failure and major adverse cardiovascular events remained low among individuals with good adherence to comprehensive treatment.
Renal function remained stable in the majority of patients receiving SGLT2 inhibitors, while urinary albumin excretion decreased, suggesting improved renal protection.
Patients who actively participated in structured lifestyle modification programs demonstrated significantly better metabolic outcomes than individuals with poor adherence to dietary recommendations or physical activity.
The present study demonstrates that comprehensive management of patients with T2DM, obesity, and elevated cardiovascular risk provides significant clinical benefits beyond glucose control alone. Modern treatment strategies should focus on integrated risk reduction rather than isolated correction of hyperglycemia.
Insulin resistance remains the central pathological mechanism linking obesity, diabetes, hypertension, dyslipidemia, and cardiovascular disease. Excess visceral adipose tissue promotes chronic inflammation, endothelial dysfunction, oxidative stress, and accelerated atherosclerosis. Therefore, interventions targeting weight reduction simultaneously improve multiple metabolic abnormalities.
Lifestyle modification continues to represent the foundation of successful management. Even moderate weight reduction substantially improves insulin sensitivity, decreases inflammatory activity, lowers blood pressure, and reduces cardiovascular risk. Long-term adherence to healthy dietary patterns and regular exercise remains essential for sustained therapeutic success.
The introduction of GLP-1 receptor agonists and SGLT2 inhibitors has significantly changed the management of high-risk diabetic patients. Unlike conventional glucose-lowering medications, these therapies provide additional cardiovascular and renal protection while promoting weight reduction and reducing hospitalization for heart failure.
Multidisciplinary care is another key determinant of successful long-term outcomes. Collaboration among endocrinologists, cardiologists, nephrologists, dietitians, diabetes educators, psychologists, and primary care physicians facilitates individualized treatment planning, improves medication adherence, and enables early identification of complications.
Digital health technologies, including continuous glucose monitoring, telemedicine consultations, wearable activity trackers, and electronic decision-support systems, further strengthen chronic disease management by allowing continuous monitoring and personalized treatment adjustment.
Future management strategies are expected to integrate genomic profiling, metabolomics, artificial intelligence, and precision medicine to identify patients at greatest cardiovascular risk and optimize individualized therapeutic interventions.
Patients with type 2 diabetes mellitus, obesity, and high cardiovascular risk require comprehensive, patient-centered management addressing metabolic, cardiovascular, renal, and lifestyle factors simultaneously.
Early identification of cardiovascular risk, aggressive management of obesity, optimization of glycemic control, treatment of hypertension and dyslipidemia, and the use of evidence-based therapies such as GLP-1 receptor agonists and SGLT2 inhibitors significantly improve long-term clinical outcomes.
A multidisciplinary approach supported by modern diagnostic technologies, digital health tools, and individualized treatment strategies offers the greatest opportunity to reduce cardiovascular complications, preserve organ function, improve quality of life, and decrease premature mortality among patients with complex metabolic disease.
[1] American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S1–S350.
[2] European Association for the Study of Diabetes, American Diabetes Association. Management of Hyperglycemia in Type 2 Diabetes, 2024 Consensus Report. Diabetes Care. 2024.
[3] Kidney Disease: Improving Global Outcomes. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(Suppl 5):S1–S127.
[4] European Society of Cardiology. 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes. Eur Heart J. 2023.
[5] American Association of Clinical Endocrinology. Clinical Practice Guideline for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocr Pract. 2022;28(10):923–1049.
[6] Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2024: A Consensus Report by the ADA and EASD. Diabetes Care. 2024.
[7] Rubino F, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes. Diabetes Care. 2022;45(12):3075–3090.
[8] Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.
[9] Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
[10] Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373(22):2117–2128.
[11] Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER Trial). N Engl J Med. 2016;375(4):311–322.
[12] Gerstein HC, et al. Dulaglutide and cardiovascular outcomes (REWIND Trial). Lancet. 2019;394(10193):121–130.
[13] Harrison's Principles of Internal Medicine. McGraw-Hill; 2022.
[14] Joslin's Diabetes Mellitus. Wolters Kluwer; 2024.
[15] World Health Organization. Diabetes. Geneva: WHO; 2025.
[16] International Diabetes Federation. IDF Diabetes Atlas. 11th ed. Brussels: IDF; 2024.
[17] European Association for the Study of Obesity. Clinical Practice Guidelines for Adult Obesity Management. 2024.
[18] American Heart Association. Guideline for the Primary Prevention of Cardiovascular Disease in Diabetes. Circulation. 2024.
[19] Med1.uz. 2-tip qandli diabet: zamonaviy diagnostika va davolash. Available from: https://med1.uz/articles/endokrinologiya/2-tip-qandli-diabet
[20] Med1.uz. Semizlik va metabolik sindromni kompleks boshqarish. Available from: https://med1.uz/articles/endokrinologiya/semizlik
[21] Med1.uz. Diabetda yurak-qon tomir xavfini kamaytirish strategiyalari. Available from: https://med1.uz/articles/kardiologiya/diabet-kardiovaskulyar-xavf
[22] Med1.uz. GLP-1 retseptor agonistlari va SGLT2 ingibitorlarining klinik ahamiyati. Available from: https://med1.uz/articles/endokrinologiya/glp1-sglt2
[23] Med1.uz. Diabetik bemorlarda ovqatlanish va turmush tarzini o‘zgartirish. Available from: https://med1.uz/articles/endokrinologiya/parhez
[24] Med1.uz. Qandli diabetda laborator monitoring va HbA1c nazorati. Available from: https://med1.uz/articles/laboratoriya/hba1c
[25] Med1.uz. Diabet va semizlikda kompleks davolash tamoyillari. Available from: https://med1.uz/articles/endokrinologiya/kompleks-davolash
[26] Med1.uz. Diabetik bemorlarni uzoq muddatli kuzatish va profilaktika. Available from: https://med1.uz/articles/endokrinologiya/monitoring